Peptigrade

Neuroendocrine & Social Cognition

Oxytocin

Oxytocin — cyclic nonapeptide Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (disulfide Cys1-Cys6)·Also known as: Pitocin, Syntocinon, OXT, alpha-hypophamine, oxt

FDARegulatory status

FDA-approved (as Pitocin and generic oxytocin injection) for labor induction/augmentation and control of postpartum hemorrhage — labeled as IV/IM parenteral use only. No FDA-approved intranasal, oral, or sublingual oxytocin product exists in the United States as of April 20, 2026. All psychiatric, autism, and social-cognition uses of intranasal or compounded oxytocin are off-label.

WADARegulatory status

Not listed as a prohibited substance on the 2026 WADA Prohibited List. Oxytocin is not on S2 (peptide hormones and growth factors) or S4 (hormone and metabolic modulators) and is therefore permitted under current anti-doping rules.

Regulatory note ·Pitocin (injectable oxytocin) has been FDA-approved since 1980 and is on the WHO Essential Medicines List for obstetric use. The landmark intranasal autism trial (SOARS-B, NEJM 2021, Sikich et al., n=290) was null at the population level; Parker 2017 (Stanford, n=32) showed responder-subgroup benefit in children with low baseline plasma oxytocin. No major regulator has approved intranasal oxytocin for ASD, social anxiety, schizophrenia, or PTSD. Compounded intranasal oxytocin is dispensed by US 503A pharmacies under off-label prescription; bioavailability to CNS via intranasal route remains an active methodological controversy (Leng & Ludwig 2016; Quintana 2021).

§ The quick take

TL;DR · Editor’s summary

Oxytocin is the rare peptide on this site with an A-grade indication: injectable oxytocin (Pitocin) has been FDA-approved for labor induction/augmentation and postpartum hemorrhage since 1980, and the WHO lists it as the first-line uterotonic for third-stage management. Obstetric efficacy is not in dispute and is supported by decades of RCT and registry data. Everything else is a different story. The SOARS-B trial (Sikich et al., NEJM 2021, n=290 children and adolescents with ASD, 24-week placebo-controlled) was null on its ABC-mSW primary endpoint — the largest and most rigorous intranasal-oxytocin autism trial to date.

Parker et al. 2017 (Stanford, n=32) had earlier shown benefit concentrated in children with low baseline plasma oxytocin; the responder-subgroup story is plausible precision-medicine signal but does not rehabilitate a null Phase 2/3. A 2024 meta-analysis (Ooi et al.) found a small positive pooled effect on social outcomes but explicitly flagged publication-bias inflation. Single-dose laboratory studies of trust, eye-gaze, and amygdala reactivity in healthy adults (Kosfeld 2005 and its imitators) have failed to replicate robustly. The deeper methodological controversy — argued forcefully by Leng & Ludwig (2016) and Quintana (2021) — is whether intranasal dosing produces centrally active CNS concentrations at all.

Pharmacokinetics in peripheral plasma after intranasal delivery are modest; CSF evidence is mixed; the molecule's short (~3-minute) plasma half-life and poor blood-brain barrier penetration remain unresolved. Oxytocin is not WADA-prohibited. It is a real FDA drug with a real obstetric indication and a contested psychiatric/social-cognition research program.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Oxytocin, sorted by strength of evidence.

A

Labor induction & augmentation

Strong

FDA-approved since 1980; Cochrane reviews and ACOG Practice Bulletin 107 (reaffirmed 2023) support IV oxytocin as first-line for induction and augmentation. Decades of RCT and registry data across millions of deliveries. Dose-response and adverse-event profile (tachysystole, hyponatremia at high cumulative doses) well characterized.

180 studiesUpdated 2026-04-20
A

Control of postpartum hemorrhage (PPH)

Strong

WHO recommends 10 IU IM/IV oxytocin as first-line uterotonic for active management of third stage of labor. Widmer 2018 (WHO CHAMPION trial, n=29,645) established heat-stable carbetocin non-inferiority vs oxytocin for PPH prevention. Oxytocin itself is the reference standard.

95 studiesUpdated 2026-04-20
A

Milk ejection (let-down) in lactation

Strong

Physiology established since du Vigneaud 1953 Nobel-winning synthesis. Intranasal oxytocin (Syntocinon spray) was marketed for this indication for decades; discontinued for commercial rather than efficacy reasons. Mechanism: myoepithelial cell contraction via OXTR/Gq/PLC/Ca2+.

60 studiesUpdated 2026-03-28
C

Social behavior in autism spectrum disorder

Mixed

SOARS-B (Sikich 2021, NEJM, n=290, 24-week RCT) showed NO significant between-group difference on the ABC-mSW primary endpoint. Parker 2017 (n=32) and follow-up analyses suggest responder benefit in children with low baseline plasma oxytocin. 2024 meta-analysis (Ooi et al., Psychoneuroendocrinology) found small positive pooled effect but flagged publication bias and inflated summary sizes.

32 studiesUpdated 2026-04-15
C

Social anxiety & trust in healthy adults

Mixed

Single-dose intranasal lab studies (Kosfeld 2005, Nature; Domes 2007) showed trust-game and amygdala-reactivity effects that have failed to replicate consistently. Leng & Ludwig 2016 (Biological Psychiatry) questioned whether intranasal dosing produces CNS-relevant concentrations at all. No Phase 3 program has advanced.

48 studiesUpdated 2026-02-18
D

PTSD symptom reduction

Weak

Small pilot and Phase 2 studies (Frijling 2017; Koch 2016) report mixed effects on amygdala reactivity and symptom scales. No adequately powered Phase 3 RCT. Dose, timing, and route remain unsettled.

14 studiesUpdated 2026-01-30
D

Schizophrenia negative symptoms

Weak

Systematic reviews (Williams & Burkner 2017; Oya 2016) of small RCTs show inconsistent and at-best modest effects on PANSS negative-symptom subscale. Signal does not clear C threshold under our rubric given replication failures.

18 studiesUpdated 2026-01-14
Ins.

Pair-bonding and long-term partnership quality

Insufficient

Mechanism extrapolated from prairie vole (Microtus ochrogaster) OXTR knockout models (Young & Wang 2004; Berendzen 2023 CRISPR null-mutant work showed residual pair-bonding, complicating the canonical story). No controlled human trial of exogenous oxytocin has demonstrated durable relationship-quality effects.

8 studiesUpdated 2026-01-10

§ Why this grade

Sub-scores for this outcome.

Labor induction & augmentation

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

5 / 5

OXTR on uterine myometrium, Gq/PLC/IP3/Ca2+/MLCK cascade, and the positive-feedback Ferguson reflex are textbook physiology. Dose-response and receptor density changes across gestation are well characterized (Gimpl & Fahrenholz 2001; Arrowsmith & Wray 2014).

Human studies (count + quality)

5 / 5

Decades of RCT, pragmatic trial, and registry data across millions of deliveries. ACOG Practice Bulletin 107 (reaffirmed 2023) and multiple Cochrane reviews synthesize the evidence. Dose titration protocols (low-dose vs high-dose IV oxytocin) have themselves been subjected to head-to-head RCTs.

Effect vs placebo

5 / 5

Labor progression and cesarean-avoidance outcomes relative to expectant management are well quantified. Effect size is clinically decisive in the induction indication.

Long-term safety data

4 / 5

Neonatal and maternal outcomes are tracked in national registries globally. Associations with neonatal hyperbilirubinemia and maternal water intoxication at high cumulative doses are recognized. The theoretical epigenetic OXTR signal in offspring of induced labor (Kenkel 2021 preclinical) has not translated to a documented human safety signal.

Side effect profile

4 / 5

Tachysystole, uterine hyperstimulation with fetal heart-rate changes, and hyponatremia at high cumulative doses are the recognized adverse events. Modern low-dose protocols substantially mitigate these. Rare anaphylactoid reactions reported.

Regulatory status

5 / 5

FDA-approved since 1980; WHO Essential Medicines List; on the formulary of every obstetric unit in every high-income country.

§ What the science says

How Oxytocin
works.

Plain-English explanation of the molecule and its proposed mechanism, written at an 8th-grade reading level so anyone can engage with it. Every claim is linked to a primary source below.

What it is

Oxytocin is a cyclic nonapeptide (sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, molecular formula C43H66N12O12S2, MW 1007.19 Da, CAS 50-56-6, PubChem CID 439302) synthesized in magnocellular neurons of the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus and released from the posterior pituitary. A disulfide bridge between Cys1 and Cys6 closes a six-member ring essential for OXTR binding; reduction of the bridge abolishes activity. Vincent du Vigneaud's 1953 synthesis won the 1955 Nobel Prize in Chemistry and established it as the first peptide hormone to be chemically synthesized. It is structurally nearly identical to arginine vasopressin (AVP), differing by only two residues, which produces measurable OXTR/V1aR cross-reactivity and complicates selective-agonist interpretation. One IU of oxytocin corresponds to approximately 1.68 micrograms of pure peptide. Plasma half-life is approximately 3-5 minutes; degradation is by oxytocinase (leucyl/cystinyl aminopeptidase) in liver, kidney, and during pregnancy the placenta.

How it works

  1. 01

    OXTR is a class A GPCR with dual G-protein coupling

    The oxytocin receptor (OXTR) is a seven-transmembrane rhodopsin-family G-protein-coupled receptor that preferentially couples to Gαq/11 but also engages Gi/o depending on cellular context. Gimpl and Fahrenholz (2001, Physiological Reviews) remains the definitive OXTR pharmacology review; Busnelli & Chini (2018, Frontiers in Neuroscience) updated the dual-coupling picture, showing that OXTR can produce opposing downstream responses in the same cell depending on which G-protein arm dominates. This biased-agonism profile is a significant complication for interpreting behavioral oxytocin effects.

  2. 02

    Gq/PLC/IP3-DAG cascade drives Ca2+ mobilization

    Canonical signaling proceeds via Gαq activation of phospholipase C, which hydrolyzes PIP2 to IP3 and DAG. IP3 binds ER IP3 receptors and releases intracellular Ca2+; DAG activates PKC. In uterine myometrium this drives MLCK-mediated actin-myosin contraction — the mechanism of Pitocin's obstetric effect. In mammary myoepithelial cells it drives the milk ejection reflex. The Ca2+/PKC arm also engages MAPK, CaMKII, and CREB-dependent transcription, linking acute firing to longer-term cellular adaptation.

  3. 03

    Central release is site-specific and pulsatile, not diffuse

    Magnocellular PVN/SON neurons fire in high-frequency bursts that produce pulsatile oxytocin release into circulation during parturition and suckling (Ferguson reflex). Parvocellular PVN neurons project centrally to the nucleus accumbens, amygdala, VTA, and prefrontal cortex. Modern optogenetic and fiber-photometry work (reviewed in Jurek & Neumann 2018, Physiological Reviews) shows that central release is spatially and temporally specific — not a single brain-wide 'oxytocin bath.' This is critical for interpreting intranasal dosing: a diffuse peripheral elevation is not a pharmacological substitute for circuit-specific endogenous release.

  4. 04

    The blood-brain barrier and intranasal controversy

    Peripheral oxytocin penetrates the blood-brain barrier poorly. Leng & Ludwig (2016, Biological Psychiatry) argued that typical intranasal doses (24-48 IU) raise CSF oxytocin only modestly and inconsistently, and that most behavioral effects may be mediated peripherally (via vagal afferents, cardiac OXTR, or gut) rather than by direct central action. Quintana et al. (2021, Molecular Psychiatry) reviewed the dose-route literature and recommended reconsidering sublingual, lingual, and systemic administration. Leong et al. (2021) using microdialysis in monkeys provided some evidence that intranasal delivery can reach limbic targets, but the magnitude and translational relevance remain debated.

  5. 05

    Interactions with serotonin, dopamine, and the HPA axis

    Oxytocin modulates neurotransmitter systems rather than acting in isolation. It enhances serotonin release in the dorsal raphe (implicated in anxiolytic effects), interacts with mesolimbic dopamine in the VTA and nucleus accumbens (implicated in social-reward salience), and attenuates HPA-axis stress response via PVN CRH suppression. These interactions are the mechanistic rationale for psychiatric trials but also explain why single-system interpretations of oxytocin action are usually wrong.

  6. 06

    What is NOT settled about the mechanism

    OXTR-ligand selectivity versus AVP receptors (V1aR, V1bR, V2R) is imperfect at supraphysiologic doses — the two peptides differ by only two residues. Human CNS pharmacokinetics after intranasal, sublingual, and IV dosing are not definitively characterized. The prairie vole story that underpinned much of the social-bonding literature has been complicated by Berendzen et al. (2023, Neuron) showing that OXTR knockout voles still form pair bonds, implying redundant pathways. Human genetic-variant (OXTR rs53576 and related SNPs) effects on social phenotypes are weaker than early reports suggested.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Labor induction and augmentation

    FDA-approved (Pitocin, 1980); ACOG Practice Bulletin 107

  • Postpartum hemorrhage prevention and treatment

    FDA-approved; WHO recommended first-line uterotonic

  • Milk ejection / lactation support

    Intranasal Syntocinon historically marketed; discontinued commercially, not for efficacy

  • Autism spectrum disorder — social communication

    Phase 2/3 null (SOARS-B, NEJM 2021, n=290); responder subgroup signal (Parker 2017)

  • Social anxiety and trust in healthy adults

    Laboratory single-dose studies since Kosfeld 2005; replication inconsistent

  • Post-traumatic stress disorder

    Phase 2 pilots (Frijling 2017, Koch 2016); no Phase 3

  • Schizophrenia — negative symptoms

    Small RCTs with mixed results (Williams & Burkner 2017 systematic review)

  • Prader-Willi syndrome — social and feeding behavior

    Early Phase 2 (Miller 2017, Hollander 2017); no definitive efficacy

  • Pair bonding / relationship quality

    Extrapolated from prairie vole models; no durable human trial

  • Skeletal muscle antiproteolytic / metabolic effects

    Preclinical (Gonzalez-Rodriguez 2023); no human program

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    Whether intranasal oxytocin reliably reaches centrally active CNS concentrations in humans is unresolved. Leng & Ludwig 2016 and Quintana 2021 argued the field has built on an unexamined pharmacokinetic assumption; peripheral vs central mediation of reported behavioral effects has not been cleanly separated.

  • !

    No adequately powered Phase 3 RCT exists for any psychiatric or social-cognition indication. SOARS-B was the largest ASD trial and was null at the population level — a responder-subgroup biomarker (low baseline plasma oxytocin) is suggestive but has not been prospectively validated in a new trial.

  • !

    Optimal route of administration for CNS indications is unsettled. Intranasal, sublingual, buccal, lingual, IV, and subcutaneous routes have all been trialed with no consensus on bioavailability to target circuits.

  • !

    Long-term safety of repeated intranasal or compounded oxytocin dosing in pediatric and adolescent populations is uncharacterized. SOARS-B provided 24-week safety data but longer-exposure human cohorts do not exist.

  • !

    OXTR/V1aR cross-reactivity at typical dosing is incompletely quantified in humans. Behavioral effects attributed to OXTR engagement may partially reflect vasopressin-receptor activation, which complicates mechanistic interpretation.

  • !

    The prairie vole pair-bonding mechanism — long cited as the molecular basis for human oxytocin-in-relationships claims — has been complicated by Berendzen 2023 showing residual pair bonding in OXTR-knockout voles. Whether the human extrapolation ever had the mechanistic grounding it claimed is now an open question.

  • !

    Endogenous oxytocin measurement in plasma and saliva is methodologically fraught (Leng & Sabatier 2016). Much of the correlational human literature relating endogenous oxytocin levels to social phenotypes may be measurement-artifact-driven.

  • !

    Drug-drug interactions with SSRIs, antipsychotics, and the HPA-axis pharmacology typical in the psychiatric populations where oxytocin is most studied are essentially unexamined in controlled trials.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Oxytocinand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Oxytocin: What the Research Actually Shows (and Doesn't)

    Huberman Lab·PhD Neurobiology, Stanford

    Walks through the obstetric vs social-cognition evidence split and is explicit that SOARS-B was null. Discusses the intranasal pharmacokinetic controversy raised by Leng & Ludwig.

    Verified credentials

  • SOARS-B Trial Results Explained — Intranasal Oxytocin in Autism

    The Transmitter (Spectrum)·Science journalism, peer-reviewed editorial process

    Covers the 2021 NEJM null result and the responder-subgroup reanalysis. Notes that the field has pivoted toward blood-brain-barrier-permeable small molecules that stimulate endogenous oxytocin release rather than exogenous intranasal dosing.

    Verified credentials

  • The 'Love Hormone' Is Not What You Think

    Anonymous wellness influencer·Unverified

    Typical overstated-benefit framing. Claims about 'cuddle hormone' relationship effects in humans are not supported by controlled trials. Treat as marketing content, not evidence.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 18 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder

    Sikich L, Kolevzon A, King BH, et al. · N Engl J Med · 2021

    RCTPMID 34347950
  2. [02]

    Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism

    Parker KJ, Oztan O, Libove RA, et al. · Proc Natl Acad Sci USA · 2017

    RCTPMID 28761157
  3. [03]

    The Oxytocin Receptor: From Intracellular Signaling to Behavior

    Jurek B, Neumann ID · Physiol Rev · 2018

    Systematic reviewPMID 28844237
  4. [04]

    The oxytocin receptor system: structure, function, and regulation

    Gimpl G, Fahrenholz F · Physiol Rev · 2001

    Systematic reviewPMID 11274341
  5. [05]

    Intranasal Oxytocin: Myths and Delusions

    Leng G, Ludwig M · Biol Psychiatry · 2016

    Systematic reviewPMID 26254593
  6. [06]

    Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research

    Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B · Mol Psychiatry · 2021

    Systematic reviewPMID 33230205
  7. [07]

    Molecular, modulatory, and structural diversity of oxytocin receptor signalling and its implication for clinical trials outcome

    Busnelli M, Chini B · Curr Top Behav Neurosci / Front Endocrinol · 2018

    Systematic reviewPMID 29434229
  8. [08]

    Oxytocin increases trust in humans

    Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E · Nature · 2005

    RCTPMID 15931222
  9. [09]

    Oxytocin for schizophrenia spectrum disorders

    Williams DR, Burkner PC · Schizophr Res · 2017

    Meta-analysisPMID 29277247
  10. [10]

    Oxytocin receptor is not required for social attachment in prairie voles

    Berendzen KM, Sharma R, Mandujano MA, et al. · Neuron · 2023

    AnimalPMID 37045086
  11. [11]

    Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth (CHAMPION trial)

    Widmer M, Piaggio G, Nguyen TMH, et al. · N Engl J Med · 2018

    RCTPMID 29540273
  12. [12]

    The effects of oxytocin on social and routinized behaviors in autism: a systematic review and meta-analysis

    Ooi YP, Weng SJ, Magiati I, et al. · Psychoneuroendocrinology · 2024

    Meta-analysisPMID 38735203
  13. [13]

    Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder (SOARS-B)

    Sikich L, Kolevzon A, King BH, et al. · N Engl J Med · 2021

    RCTDOI
  14. [14]

    The Oxytocin Receptor: From Intracellular Signaling to Behavior

    Jurek B, Neumann ID · Physiol Rev · 2018

    Systematic reviewDOI
  15. [15]

    Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)

    Duke University / Sikich L · ClinicalTrials.gov · 2021

    RegistrationTrial
  16. [16]

    Pitocin (oxytocin injection) FDA prescribing information

    U.S. Food and Drug Administration / JHP Pharmaceuticals · FDA · 2026

    RegulatoryLink
  17. [17]

    ACOG Practice Bulletin 107: Induction of Labor (reaffirmed 2023)

    American College of Obstetricians and Gynecologists · Obstet Gynecol · 2023

    RegulatoryLink
  18. [18]

    WADA 2026 Prohibited List (in force January 1, 2026) — oxytocin not listed

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

Kisspeptin-10

Adjacent hypothalamic neuropeptide — operates on the reproductive/GnRH axis rather than the social-cognition axis, but shares the neuroendocrine-integrator framing and the same methodological questions about peripheral vs central dosing.

Read its grades

Compare

PT-141 (Bremelanotide)

FDA-approved melanocortin agonist for female sexual-arousal disorder. Closest approved-drug analogue when users are searching oxytocin for relationship/intimacy use cases — has real Phase 3 efficacy data that oxytocin lacks for these indications.

Read its grades

Compare

Melanotan II

The unapproved cousin of PT-141. Users comparing oxytocin-for-intimacy claims often cross-shop MT-II; worth the contrast in evidence quality and regulatory status.

Read its grades

Where to research further

Looking for Oxytocin
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →